China’s Sciwind Biosciences raises $29 mln in funding led by Legend Capital

02/15/2019 11:28:00 AM (GMT)

Chinese drug research and development company Sciwind Biosciences has raised 200 million yuan ($29 million) in Series A funding.

The round was led by China-based Legend Capital, a venture capital subsidiary of Legend Holdings Ltd.

Existing backers in the round included Shenzhen Shiyu Investment Management Co. and Beijing Kawin Technology Share-Holding Co.

The commitment was made in Legend Capital’s $600 million Information Technology Fund that will target information technology and healthcare companies in China and China-related firms.

Sciwind Biosciences

All success stories are prepared by Investsize editors which is selecting elite and remarkable information from press releases and anonymous news sources.There is no charge applied for any success stories which is published . Those published success stories are not investment advices and doesnt offer recommendations Alternate Text